|
|
LUMIGAN®, approved by the U.S. Food and Drug Administration (FDA) in 2001, is indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Based on its efficacy and safety profile demonstrated over five years, LUMIGAN® received a first-line indication from the FDA in 2006 and is now used as an initial treatment in an increasing number of patients. LUMIGAN® offers a once-a-day dosing regimen. Maintaining once-daily dosing can be convenient for patients.
|